21/10/25 -"Our EPS for 2025 benefitted from the positive change in the fair value of financial assets of SEK 731m, which was primarily driven by the revaluation of biotech Enveda stake, from SEK 814m to SEK ..."
Pages
63
Language
English
Published on
21/10/25
You may also be interested by these reports :
21/10/25
Our NAV does not change much after, and despite, the listing of TKMS yesterday, 49.9% distributed to TK AG shareholders. Actually, our valuation ...
21/10/25
Our EPS for 2025 benefitted from the positive change in the fair value of financial assets of SEK 731m, which was primarily driven by the revaluation ...
21/10/25
Edenred reported Q3 revenue slightly above consensus and demonstrated accelerated like-for-like growth thanks to strong operational momentum. This ...
21/10/25
We have revised our peer list by removing several companies to ensure a more representative industry average. Amadeus IT Group and Sage were removed ...